Price
No data yet.
Social Signal Score
Revenue
$522.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James R. McCullough
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 102
- Beta
- 2.10
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -81.21
Financials
Revenue
$522.0K-15.7%Net Income
$-4.73MEBITDA
$-4.03MFree Cash Flow
$-3.84MEPS (diluted)
$-0.08Shares Outstanding (diluted)
52.85M+292.8%Operating Expenses
$4.19MCash & Debt
$909.0KReturn of Capital
$0.00Revenue by Segment (annual)
$10.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $2.29M | $-33.46M | $-0.62 |
| 2023 | $3.40M | $-45.61M | $-1.10 |
| 2022 | $2.97M | $-45.28M | $-1.24 |
| 2021 | $1.49M | $-34.73M | $-0.98 |
| 2020 | $0.00 | $-9.84M | $-0.34 |
| 2019 | $0.00 | $-42.30M | $-1.98 |
| 2018 | $0.00 | $-1.25M | $-0.06 |
Valuation
RNLXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
115-4.17%Social Signal Score
Mentions (2)
- Newsproactiveinvestors.co.uk·6h ago·Positive
Renalytix rises 7% as UBS holding grows and CEO buys shares Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9)) advanced to 6p, up 7%, alongside disclosures of a larger UBS holding and share purchases by chief executive James McCullough. The kidney diagnostics company reported UBS voting rights of 6.62%, up from 5.17% in the previous notification, in a filing released on Friday.
View source ↗ - Newsproactiveinvestors.co.uk·3d ago·Positive
Renalytix shares surge 19% as trading resumes after cash call Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) jumped 19% to 5p on Tuesday as trading resumed following a fundraise that pulled in £10.5 million for the AIM-listed diagnostics firm. The company had paused trading in its shares at the start of September while it lined up new investment, including a placing with institutional backers and an offer allowing existing retail shareholders to buy in too.
View source ↗
Earnings
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 12$-0.08 vs $-0.03miss
- Mon, Sep 30$-0.04 vs $-0.05beat
- Wed, May 15$-0.08 vs $-0.07miss
- Wed, Feb 14$-0.09 vs $-0.09beat
- Tue, Nov 14$-0.11 vs $-0.11beat
- Thu, Sep 28$-0.10 vs $-0.13beat
Estimates and results for RNLX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RNLX officers and directors.
No open-market trades in the recent filings. All 45 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RNLX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.